Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Assets (2021 - 2025)

Kezar Life Sciences' Assets history spans 5 years, with the latest figure at $125.3 million for Q1 2025.

  • For Q1 2025, Assets fell 37.1% year-over-year to $125.3 million; the TTM value through Mar 2025 reached $125.3 million, down 37.1%, while the annual FY2024 figure was $144.7 million, 34.6% down from the prior year.
  • Assets for Q1 2025 was $125.3 million at Kezar Life Sciences, down from $144.7 million in the prior quarter.
  • Across five years, Assets topped out at $317.5 million in Q2 2022 and bottomed at $125.3 million in Q1 2025.
  • The 5-year median for Assets is $217.9 million (2021), against an average of $214.5 million.
  • The largest annual shift saw Assets surged 132.85% in 2022 before it plummeted 37.1% in 2025.
  • A 5-year view of Assets shows it stood at $217.9 million in 2021, then surged by 37.46% to $299.6 million in 2022, then fell by 26.15% to $221.2 million in 2023, then crashed by 34.6% to $144.7 million in 2024, then dropped by 13.42% to $125.3 million in 2025.
  • Per Business Quant, the three most recent readings for KZR's Assets are $125.3 million (Q1 2025), $144.7 million (Q4 2024), and $164.1 million (Q3 2024).